Effector begins Phase II trial of eFT508 plus Bavencio

Effector Therapeutics Inc. (San Diego, Calif.) began a Phase II trial of eFT508 with or without PD-L1 inhibitor Bavencio avelumab (MSB0010718C, PF-06834635)

Read the full 226 word article

User Sign In